Drug Trial Radar · NCT07660640
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Last checked: Nov 19, 2026Latest source record: Jun 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Enrolling by invitation
Enrollment
88
Planned (sponsor's estimate)
Start
Mar 3, 2026
Primary completion
Jul 30, 2031
Study completion Aug 30, 2031
Sponsor
- Lead sponsor
- Perceive Biotherapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
Conditions
- Age-Related Macular Degeneration (AMD)
- Non-Neovascular Age-Related Macular Degeneration
Interventions
observational studyOther
No intervention - observational study
VOY-101Biological
One-time intravitreal injection of VOY-101.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of ocular and systemic VOY-101 related AEsTime frame: 3 years
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Ophthalmic Consultants of Boston
Boston, Massachusetts
Retina Consultants of Texas
Bellaire, Texas
University of Utah
Salt Lake City, Utah
Sourasky Medical Center - Ichilov
Tel Aviv, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.